1. Introduction {#sec1}
===============

Atherosclerosis is the most common vascular pathology in patients with cardiovascular events, which leads to mortality in developed countries. There are various tools to evaluate the diseased populations for prediction, diagnosis, and risk stratification. Among asymptomatic patients, the predictive and prognostic values of calcium scores via electron beam computed tomography (EBCT) were proved in previous studies, either as an addition to the FRS or to C-reactive protein \[[@B1]\], or used alone \[[@B2]\]. Because coronary calcification is not uncommon in patients with myocardial ischemia, multidetected computed tomography (MDCT) has become a more useful modality for coronary heart disease evaluation. On the other hand, evolving evidence showed that NAFLD may actually represent metabolic syndrome in liver \[[@B3]\]. The existence and severity of NAFLD by liver biopsy as a gold standard also proved to be association with MRS \[[@B4], [@B5]\]. Recent studies demonstrated that NAFLD could further predict cardiovascular diseases or even involved the pathophysiologic process of atherosclerosis \[[@B4]\].

In our study, we sought to define the correlation between the extent of NAFLD, cardiovascular risks, and MDCT-acquired calcium score. We also tried to examine the role of NAFLD beyond other clinical factors in the prediction and identification of coronary calcification.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects {#sec2.1}
-------------------

We subsequently enrolled 342 non-alcoholism from outpatient clinics or subjects underwent health evaluation who had both MDCT examination for cardiovascular risk stratification as well as abdominal ultrasonography for the detection of fatty liver disease. This study was proved by the ethics committee of Mackay Memorial Hospital, Taipei, Taiwan (09MMHIS038), in accordance with the Declaration of Helsinki.

2.2. Data Collection and Laboratory Parameters {#sec2.2}
----------------------------------------------

Anthropometric measurements including body height, body weight, waist circumference, and blood pressures at rest were taken by a registered technician who was blinded to the other test results. Body mass index (BMI) was derived from the ratio of weight to height squared. Body surface area (BSA) was calculated according to formula of DuBois. Review of medical history, physical examination, 12-lead electrocardiogram, and chest plain film were all performed by study physicians. High-sensitivity C-reactive protein (hs-CRP) levels were determined by a latex particle-enhanced immunoassay using Elecsys 2010 method (Roche, Mannheim, Germany). The other laboratory data, including a lipid profile and a renal function test, was obtained by a Hitachi 7170 Automatic Analyzer (Hitachi Corp. Hitachinaka Ibaraki, Japan). Immunoreactive insulin was measured by radioimmunoassay (PerkinElmer Automatic Gamma Counter 1470; PerkinElmer, Waltham, MA, USA). Insulin resistance was further defined as using the following homeostasis model equation: insulin resistance method (HOMA-IR) = fasting glucose (mmol/L) × fasting insulin (*μ*U/mL)/22.5. HbA1c level was obtained by high-performance liquid chromatography (Bio-rad Variant II; Bio-Rad Laboratories, Hercules, CA, USA). Body fat composition percentage was assessed by using a commercialized foot-to-foot bioelectrical impedance scale (Tanita Inc., Tokyo, Japan, models TBF 410GS).

2.3. Abdominal Ultrasonography for NAFLD Grading {#sec2.3}
------------------------------------------------

Abdominal ultrasonography is a validated tool to diagnose fatty liver rather than liver biopsy. The presence of fatty liver disease was detected using abdominal ultrasonography done by an experienced gastroenterologist who has no reference of the participants\' other data. Three levels adopted for evaluating the severity of fatty liver was based on 4 basic techniques (hepatorenal echo contrast, liver brightness, deep attenuation, and vascular blurring) as described from previous studies \[[@B6]\]. Right kidney echogenicity was used for the contrast of liver parenchyma echogenicity. It is normal with the same kidney cortex and liver parenchyma echogenicity. The severity of NAFLD is graded as the following: mild: minimal diffuse increase in liver brightness, but diaphragm and intrahepatic vessel contours seem normal; moderate: medium grade diffuse increase in liver brightness and mild attenuation of diaphragm and intrahepatic vessels; severe: apparent increase in echogenicity. Under the aware that fatty liver interpretation by using ultrasonic assessment may be subjective, we adopted a more strict methodology in categorizing subjects with at least moderate degree fatty liver disease as significant fatty liver disease in this study.

2.4. Coronary Calcium Score Measurement {#sec2.4}
---------------------------------------

Coronary calcification of coronary arteries was quantified by using a dedicated offline workstation (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). A coronary calcified lesion was defined as an area with a density \>130 HU and covering at least 6 pixels. Scanning was performed by a 16-slice MDCT scanner (Sensation 16, Siemens Medical Solutions, Forchheim, Germany) with 16 × 0.75 mm  collimation, rotation time 420 ms,  and tube voltage of 120 kV  in one breath hold. From the raw data, the images were reconstructed with standard kernel in 3 mm thick axial, nonoverlapping slices and 25 cm  field of view. The Agatston score method was applied by multiplying each lesion (area) by a weighted CT attenuation score in the lesion.

2.5. Definition of Framingham Risk Score {#sec2.5}
----------------------------------------

The Framingham risk score (FRS) is designed to estimate 10-year risk of developing coronary heart disease (myocardial infarction and coronary death) in adults aged 20 and older who do not have heart disease or diabetes. This tool is based on the score (Adult Treatment Panel III, ATP-III) deriving from the information of age, gender, cholesterol dysregulation, (pre) hypertension, and smoking \[[@B7]\].

2.6. Definition of Metabolic Risk Score {#sec2.6}
---------------------------------------

Similar to ATP-III criteria, abnormal metabolic components defined by the Bureau of Health Promotion, Department of Health, Taiwan were \[[@B8]\]: (1) increased waist circumference of at least 90 cm  in men and of at least 80 cm  in women; (2) abnormally elevated serum triglycerides (TG) of at least 150 mg /dL; (3) lower serum high-density lipoprotein (HDL) cholesterol of less than 40 mg /dL for men and less than 50 mg /dL for women; (4) higher fasting blood glucose level greater than 110 mg /dL; (5) elevated systolic blood pressure of at least 130 mmHg  and/or diastolic blood pressure of at least 85 mmHg , or undergoing hypertension treatment. The scoring system was calculated and presented as the numbers of abnormal items meeting the criteria, with score 0 for the absence and score 5 for the presence of all 5 abnormal metabolic components. Metabolic risk score (MRS) of 3 or more met the definition of metabolic syndrome.

2.7. Statistics {#sec2.7}
---------------

All data was presented as mean ± SD. Continuous data between groups with and without abnormal calcium score deposition were compared by using Mann-Whitney test with abnormal distribution and by Student *t-*test if in normal distribution. Categorical variables were compared by Chi square and Fisher Exact tests as appropriate. Nonparametric rank sum test was used to test the graded change of cardiovascular risks estimated by using ATP III or Framingham system over different fatty liver status. Multivariable regression model was used based on Framingham system (FRS) and ATP III (MRS) with life styles or other variables not included in the Framingham system (FRS) or ATP III (MRS) model sequentially entered to identify the independent value in predicting fatty liver disease. Receiving operative characteristic (ROC) curves were used to test the hypothesis that whether the existence of NAFLD helps provide incremental value in the detection of abnormal coronary calcium deposition beyond traditional cardiovascular risk systems. *P*  value was set at two-tailed probability, and a *P* value less than 0.05 was considered statistically significant. All analysis was done by the software package STATA 8.2 (StataCorp, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. Patients Demographics and Baseline Characteristics {#sec3.1}
-------------------------------------------------------

Of all 342 participants, 239 subjects (mean age 47 years, 27.6% female) did not have notable calcification of all coronary territories (Group I), whereas 103 subjects (mean age 52.6 years, 10% female) were with obvious coronary calcification (Group II). Main demographic data and baseline characteristics are illustrated in [Table 1](#tab1){ref-type="table"}. Subjects with abnormal calcium scores (Group II) were older with more male gender. In addition, they tended to have larger BMI, waist circumference, and higher blood pressure. Baseline biochemistry did not show significant differences between these two groups except a trend toward higher serum glucose level. MRS and FRS were also higher in group II. The prevalence of abnormal electrocardiographic patterns like ischemia or hypertrophy was higher in group II. Subjects in group II were also observed to have higher prevalence of hypertension, diabetes or hyperlipidemia medical history when compared with group I.

3.2. The Independent Predictive Value of NAFLD in Different Models {#sec3.2}
------------------------------------------------------------------

In [Figure 1](#fig1){ref-type="fig"}, we illustrated the relationship between coronary calcium score, cardiovascular risk scores, and the degree of fatty liver echogenicity. More severe fatty liver degree was observed to be associated with higher calcium scores, higher FRS and MRS (trend *P* \< 0.001). We further examined the independent value of NAFLD in the prediction of abnormal coronary calcium scores by testing different clinical variables based on FRS or MRS separately into three different models ([Table 2](#tab2){ref-type="table"}). In model 1, when other clinical variables including smoking and exercise based on the relatively insufficiency of individual scores were entered into regression model, significant fatty liver disease independently identified coronary calcium existence in either FRS group or the MRS group. In model 2, when liver function tests were together in regression model, moderate to severe fatty liver disease was still independently associated in both groups. In model 3, when body fat composition was further entered in the regression model, the presence of fatty liver disease remained statistically significantly independent in the prediction of coronary calcium existence.

3.3. The Incremental Value of NAFLD beyond Traditional Cardiovascular Risks in the Prediction of Coronary Calcium Scores {#sec3.3}
------------------------------------------------------------------------------------------------------------------------

In [Figure 2](#fig2){ref-type="fig"}, we tested the hypothesis that whether the presence of fatty liver disease could further expand the area under curve (AUC) for the discrimination of coronary artery calcification from normal subjects meaningfully. While FRS and MRS alone have an AUC of 0.67 and 0.64, the addition of NAFLD further significantly expanded the AUC to 0.71 and 0.69, respectively (*c*-statistics \< 0.05).

4. Discussion {#sec4}
=============

In this study, anthropometric data from asymptomatic people without known cardiovascular disease demonstrated a significantly positive correlation between coronary calcium score and traditional anthropometrics, blood pressure, insulin resistance, and systemic inflammation marker in terms of hs-CRP. Both estimated cardiovascular risk scores including FRS and MRS for the prediction of coronary calcification in our study by utilizing ROC analysis were similar to that in Wanamethee\'s report \[[@B9]\]. However, unique to this study, we found that more severe fatty liver disease, when assessed by abdominal ultrasonography, may serve as an independent factor even after adjustment of clinical variables and estimated cardiovascular risk scores. Furthermore, we also demonstrated that the presence of more severe degree fatty liver disease added incremental value beyond such traditional cardiovascular risks in the prediction of coronary artery calcification.

Atherosclerosis, conceptualized as a convergence of bone biology with vascular inflammatory pathobiology \[[@B10]\], can recently be assessed and quantified by extent of coronary artery calcification in terms of coronary calcification score when EBCT was clinically introduced and started to serve as a feasible surrogate marker \[[@B11]--[@B13]\]. Higher calcium scores are seen in most patients with myocardial ischemia, either symptomatic or silent \[[@B2], [@B14]\]. And the result of coronary calcium score derived from EBCT also predicts stress-related ischemia on stress nuclear images \[[@B14]\] and future cardiovascular events \[[@B2]\].

Metabolic syndrome as a medical disorder complex with a central key factor of obesity accompanied with insulin resistance has been proved as an antecedent of types of diabetes mellitus and several cardiovascular diseases \[[@B9], [@B15]--[@B20]\]. Another frequently used cardiovascular risk estimate such as Framingham score is also a widely accepted scoring system, using age, smoking, HDL, BP, and cholesterol instead of triglyceride, in predicting cardiovascular risks \[[@B1], [@B9]\]. The ATP III had suggested usage of both the metabolic risk factors plus Framingham score in determining the risk of cardiovascular events and targeting treatment goal of LDL. It is thus not surprising that NAFLD, defined as excess fat accumulation in the fat-laden hepatocytes by light microscopy which covers a broad clinical spectrum of liver diseases, be viewed as a component or consequence of metabolic syndrome \[[@B21a], [@B21b]\]. However, this "gold standard" is not clinically feasible in daily practice. In the recent years, liver ultrasound has emerged as the most common and simplest one of the alternative tools in NAFLD diagnosis \[[@B22]\].

In contrast to Caucasian, the Asian populations have shown higher prevalence of nonalcoholic steatohepatitis than alcoholic hepatitis with nearly 33% of NAFLD meet the complete diagnosis of metabolic syndrome \[[@B23]\]. In this regard, NAFLD has thus been deemed a hepatic representation of metabolic syndrome \[[@B3]\].

Recent studies have demonstrated that NAFLD patients had developed subclinical atherosclerosis when compared to nonsteatosis individuals. Further, cardiovascular disease is the second most common cause of death in NAFLD patients \[[@B4]\]. More importantly, subjects with known steatosis are associated with abnormal carotid intima-media \[[@B24]\], more vulnerable coronary plaques by MDCT \[[@B25]\], higher serum markers of inflammation \[[@B26]\], worse endothelial function, increased myocardial insulin resistance \[[@B27]\], decreased adiponectin concentrations, and abnormal lipoprotein metabolism \[[@B28]--[@B30]\].

Ethnic differences in MESA study, such as higher percentage of coronary calcification in Chinese than Hispanic and black groups, was suggestive of unknown mechanism influencing cardiovascular diseases \[[@B31]\]. So far, it remains inconclusive and controversial regarding the true causal relationship between NAFLD and cardiovascular diseases. Some studies had ever described that NAFLD is less likely a direct mediator of cardiovascular disease but an "epiphenomenon\" \[[@B32]\]; however, our study reported the independent role of NAFLD in predicting coronary calcification beyond traditional cardiovascular scores. This finding may have an impact on cardiovascular risk stratification or even disease process evaluation. More severe form of NAFLD could thus be viewed as an independent clinical marker for higher cardiovascular risks that may benefit from a more aggressive approach. It also deserves more efforts to work out the influence of liver fat intervention on cardiovascular diseases compared to prior reports \[[@B33], [@B34]\].

5. Conclusion {#sec5}
=============

The severity of NAFLD not only links to metabolic derangement and traditional cardiovascular risks but also independently identifies the burden of coronary atherosclerosis in terms of coronary calcification. Simple NAFLD grading by liver ultrasonography may serve as a clinically useful tool beyond conventional risk factors in cardiovascular risk stratification.

![Estimated cardiovascular risk scores and coronary calcification categorized by the severity of nonalcoholic fatty liver disease. More severe fatty liver disease was associated with higher cardiovascular risk scores by either metabolic or Framingham risk scores and coronary calcium scores.](RRP2011-586785.001){#fig1}

![Receiver operating characteristic curves demonstrated by both metabolic or Framingham risk scores and superimposed by fatty liver disease in predicting coronary calcium deposition. When presence of fatty liver disease was added on traditional cardiovascular risk scores, there was significant increase in the area under curve.](RRP2011-586785.002){#fig2}

###### 

Baseline demographic data and clinical information in our study.

                                      Calcium score zero (*N* = 239)   Calcium score abnormal (*N* = 103)   *P* value
  ----------------------------------- -------------------------------- ------------------------------------ -----------
  Age, years                          47.0 (6.4)                       52.6 (6.6)                           \<0.001
  Gender, female %                    66 (27.6)                        11 (10.6)                            
  Height, cm                          165.9 (7.5)                      167.7 (7.5)                          0.09
  Weight, kg                          65.9 (11.3)                      68.9 (10.1)                          0.008
  BMI, Kg/m^2^                        23.8 (3.1)                       24.4 (2.7)                           0.013
  Waist, cm                           81.4 (9.1)                       85.0 (7.9)                           \<0.001
  Waist to hip ratio                  0.88 (0.07)                      0.91 (0.06)                          \<0.001
  SBP, mmHg                           116.7 (14.9)                     125.1 (15.1)                         0.003
  DBP, mmHg                           74.5 (10.2)                      77.9 (9.7)                           0.002
  Biochemistry                                                                                              
   Sugar (AC), mg/dL                  93.3 (21.2)                      102.0 (20.9)                         0.086
   Sugar (PC), mg/dL                  105.9 (31.6)                     118.5 (44.4)                         0.082
   HbA1c, %                           5.8 (0.6)                        6.0 (0.6)                            0.32
   Insulin, U/mL                      6.25 (4.24)                      6.91 (3.75)                          0.046
   HOMA-IR                            1.55 (1.25)                      1.76 (1.06)                          0.016
   Cholesterol, mg/dL                 191.1 (32.9)                     196.1 (35.1)                         0.23
   LDL, mg/dL                         128.0 (31.3)                     125.8 (31.7)                         0.56
   HDL, mg/dL                         53.0 (13.7)                      49.1 (12.8)                          0.02
   TG, mg/dL                          141.9 (103)                      145.8 (85.2)                         0.74
   BUN, mg/dL                         11.8 (3.2)                       12.6 (3.7)                           0.32
   Creatinine, mg/dL                  0.91 (0.18)                      0.97 (0.18)                          0.39
   Uric Acid, mg/dL                   5.6 (1.4)                        6.1 (1.5)                            0.003
   Homocystine, mg/dL                 7.3 (2.1)                        8.4 (2.3)                            0.03
   Hs-CRP, mg/dL                      0.2 (0.35)                       0.32 (0.7)                           0.043
  ECG pattern                                                                                               
   ECG (LVH or myocardial ischemia)   41 (7.5)                         28 (13.2)                            0.016
   ECG (old infarct)                  5 (1)                            9 (4.2)                              0.002
  Medical history                                                                                           
   Smoking                            84 (24.9)                        42 (29.4)                            0.311
   HTN history                        41 (12)                          35 (23.7)                            0.001
   DM history                         11 (3.2)                         14 (9.5)                             0.004
   Hyperlipidemia                     17 (5.6)                         13 (9.6)                             0.039
   CVD                                12 (3.9)                         12 (8.9)                             0.033
  Family Hx                                                                                                 
   Family Hx HTN                      147 (43)                         62 (41.9)                            0.823
   Family Hx DM                       88 (25.8)                        42 (28.4)                            0.554
   Family Hx Stroke                   49 (14.3)                        20 (13.5)                            0.812
   Family Hx CVD                      57 (16.7)                        30 (20.3)                            0.345

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; sugar (AC): fasting glucose; sugar (PC): postprandial glucose; HOMA-IR: insulin resistance; ECG: electrocardiography; LVH: left ventricular hypertrophy; HTN: hypertension; DM: diabetes; NAFLD: nonalcoholic fatty liver disease; CVD: cardiovascular disease: Hx: history.

###### 

Multivariate logistic regression models in predicting coronary calcium deposition.

  Variables                          OR     SE     *Z*     *P*       CI 95%     
  ---------------------------------- ------ ------ ------- --------- ---------- ----------
  *Model 1*                                                                     
  FRS                                1.16   0.05   3.09    0.002     1.054599   1.268832
  BMI                                0.93   0.06   −1.23   0.218     .8193498   1.04653
  Sugar (AC)                         0.99   0.01   −0.5    0.618     .9744172   1.015514
  Drinking                           0.99   0.39   −0.02   0.981     .4557979   2.153525
  Exercise                           0.76   0.63   −0.33   0.742     .1488091   3.882643
  Fatty liver (moderate to severe)   4.47   2.66   2.52    0.012     1.393377   14.33824
  DM history                         1.92   2.15   0.58    0.563     .2114827   17.35303
                                                                                
  MRS                                1.1    0.15   0.67    0.506     .836501    1.436341
  Age                                1.16   0.03   5.16    \<0.001   1.097237   1.229447
  Sex                                4.84   2.62   2.92    0.004     1.677794   13.97886
  Drinking                           0.7    0.28   −0.88   0.381     .3176925   1.549465
  Smoking                            0.8    0.36   −0.49   0.627     .3329831   1.94089
  Exercise                           0.32   0.3    −1.21   0.225     .0488721   2.032724
  Fatty liver (moderate to severe)   3.83   2.13   2.42    0.016     1.288897   11.39297
                                                                                
  *Model 2*                                                                     
  FRS                                1.15   0.06   2.87    0.004     1.045555   1.26785
  BMI                                0.92   0.06   −1.18   0.24      .811891    1.053551
  Sugar (AC)                         0.99   0.01   −0.71   0.478     .9715331   1.013632
  Drinking                           0.77   0.33   −0.61   0.544     .3299596   1.794328
  Exercise                           0.78   0.67   −0.29   0.772     .145282    4.191667
  Fatty liver (moderate to severe)   7.36   5.35   2.75    0.006     1.769904   30.56831
  DM history                         1.71   2      0.46    0.649     .1713221   16.99859
  Viral hepatitis carrier            1.14   0.65   0.23    0.82      .3714342   3.491325
  GPT                                0.99   0.01   −0.92   0.359     .9695872   1.011263
  rGT                                1.02   0.01   1.1     0.272     .9879836   1.043843
                                                                                
  MRS                                1.06   0.16   0.37    0.71      .7835745   1.43072
  Age                                1.16   0.03   4.93    \<0.001   1.092158   1.226692
  Sex                                5.19   2.9    2.95    0.003     1.737443   15.52867
  Drinking                           0.58   0.25   −1.26   0.207     .2466988   1.353505
  Smoking                            0.8    0.38   −0.47   0.641     3155051    2.035192
  Exercise                           0.29   0.27   −1.31   0.19      .0437895   1.8624
  Fatty liver (moderate to severe)   7.43   4.95   3.01    0.003     2.014803   27.42179
  Viral hepatitis carrier            1.34   0.77   0.51    0.613     .4322222   4.144012
  GPT                                0.98   0.01   −1.41   0.159     .9619023   1.006359
  rGT                                1.01   0.01   1.01    0.312     .9861562   1.044676
                                                                                
  *Model 3*                                                                     
  FRS                                1.14   0.05   2.78    0.005     1.040021   1.253657
  BMI                                1      0.08   0.1     0.921     .8635472   1.176196
  Sugar (AC)                         0.99   0.01   −0.67   0.505     .9722974   1.013941
  Drinking                           0.73   0.32   −0.74   0.461     .3102782   1.70035
  Exercise                           0.4    0.39   −0.94   0.347     .0574678   2.726738
  Fatty liver (moderate to severe)   6.77   4.95   2.62    0.009     1.61448    28.35676
  DM history                         1.46   1.68   0.33    0.743     .1532743   13.87366
  Viral hepatitis carrier            1.31   0.77   0.47    0.641     .418516    4.118456
  GPT                                0.99   0.01   −0.87   0.385     .9708703   1.011461
  rGT                                1.02   0.01   1.03    0.302     .9870173   1.043093
  Body fat                           0.92   0.04   −1.94   0.053     .8456979   1.000979
                                                                                
  MRS                                1.12   0.18   0.72    0.473     .8203864   1.532548
  Age                                1.16   0.03   4.97    \<0.001   1.092734   1.226381
  Sex                                3.1    2      1.76    0.078     .8790155   10.95577
  Drinking                           0.58   0.25   −1.25   0.211     .2463022   1.363246
  Smoking                            0.83   0.4    −0.38   0.702     .3256642   2.129526
  Exercise                           0.18   0.18   −1.75   0.08      .0260914   1.227528
  Fatty liver (moderate to severe)   8.58   6      3.07    0.002     2.176022   33.82722
  Viral hepatitis carrier            1.44   0.84   0.63    0.528     .4627544   4.488757
  GPT                                0.99   0.01   −1.17   0.243     .9656288   1.008901
  rGT                                1.02   0.02   1.04    0.298     .9864816   1.045414
  Body fat                           0.94   0.04   −1.57   0.117     .8679529   1.015836

FRS: Framingham risk score; MRS: metabolic risk score; *γ*-GT: *γ*-glutamyl transpeptidase; GPT: alanine aminotransferase. Other abbreviations were listed in [Table 1](#tab1){ref-type="table"}.
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